Full text

Turn on search term navigation

© 2025. This work is published under http://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

ABSTRACT

Background

FXYD3 is a Na/K‐ATPase modulator which is upregulated in pancreatic ductal adenocarcinoma (PDAC), but its prognostic role is unknown. This study evaluated FXYD3 expression in chemo‐naive patients with surgically‐resected PDAC at a single centre (1993–2014).

Method

FXYD3 expression was assessed in tumour specimens using immunohistochemistry.

Results

145 of 180 PDAC tumour specimens were FXYD3‐immunopositive (80.5%). There was no difference in median overall survival between the FXYD3 negative (27.60 months) and positive groups (25.00 months) (log‐rank p = 0.9718). FXYD3 expression correlated positively with late‐stage disease (OR 3.041, 95% CI 1.190–7.455, p = 0.0175). There was no significant association with T stage, positive lymph nodes, perineural invasion, lymphovascular invasion or histological grade.

Conclusion

Immunohistochemical FXYD3 expression does not predict survival in chemo‐naive PDAC patients, but is associated with late‐stage disease. The high rate of FXYD3 overexpression warrants therapeutic evaluation.

Details

Title
FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival
Author
Rasko, Nathalie B. 1 ; Nahm, Christopher B. 2 ; Turchini, John 3 ; Teh, Rachel 1 ; Rasmussen, Helge 4 ; Byeon, Sooin 1 ; Sahni, Sumit 5   VIAFID ORCID Logo  ; Samra, Jaswinder S. 6 ; Gill, Anthony J. 3 ; Mittal, Anubhav 7 

 Faculty of Medicine and Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia 
 Faculty of Medicine and Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia, Upper Gastrointestinal Surgical Unit, Department of Gastrointestinal Surgery, Royal North Shore Hospital, Sydney, New South Wales, Australia 
 Faculty of Medicine and Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia, Cancer Diagnosis and Pathology Group, Kolling Institute, Royal North Shore Hospital, Sydney, New South Wales, Australia 
 Faculty of Medicine and Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia, Cardiac Membrane Biology Laboratory, Kolling Institute, The University of Sydney, Sydney, New South Wales, Australia 
 Faculty of Medicine and Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia, Australian Pancreatic Centre, Sydney, New South Wales, Australia 
 Faculty of Medicine and Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia, Upper Gastrointestinal Surgical Unit, Department of Gastrointestinal Surgery, Royal North Shore Hospital, Sydney, New South Wales, Australia, Australian Pancreatic Centre, Sydney, New South Wales, Australia, Faculty of Medical and Health Sciences, Macquarie University, Sydney, New South Wales, Australia 
 Faculty of Medicine and Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia, Upper Gastrointestinal Surgical Unit, Department of Gastrointestinal Surgery, Royal North Shore Hospital, Sydney, New South Wales, Australia, Australian Pancreatic Centre, Sydney, New South Wales, Australia 
Section
RESEARCH ARTICLE
Publication year
2025
Publication date
Jan 1, 2025
Publisher
John Wiley & Sons, Inc.
e-ISSN
20457634
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3154704930
Copyright
© 2025. This work is published under http://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.